E N D Presentation Transcript GLP-1 Agonists and Cardiovascular Health Alan Mathis PharmD Candidate 2013 www.DIABETESINCONTROL.COM Part 2 of 2 Change in Triglycerides and HDL-C as Function of Weight-Change Quartile at 82 Weeks Effects of GLP-1 agonists on inflammatory markers GLP-1 agonists have been shown to reduce several inflammatory markers including plasminogen activator inhibitor-1 (PAI-1), vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1) E-selectin was not significantly reduced C-reactive protein has also been associated with increased cardiovascular disease Patients treated with exenatide showed marked decrease in c-reactive protein levels after an 82-week study (from 3.21mg/dL to 1.35 mg/dL) Kendall DM, Bhole D, Guan X, et al.: Exenatide treatment for 82 weeks reduced C-reactive protein, HbAlc, and body weight in patients with type 2 diabetes mellitus
It works by: inhibiting the enzyme tyrosinase reducing melanin formation in treated areas helping lighten hyperpigmented spots It does not affect: internal antioxidant balance liver detox pathways overall systemic melanin regulation It is a targeted external solution, not an internal support system
This article builds on that foundation with updated regulatory context and a focused informational overview of the Sprout Health platform specifically
Our guide to tirzepatide and levothyroxine covers this specific interaction
This allows the nutrient to be absorbed directly through the mucous membranes and into the small blood vessels, bypassing the digestive tract entirely
